Immunohistochemical analysis of RTKs expression identified HER3 as a prognostic indicator of gastric cancer.
Bottom Line: Analysis using a multivariate proportional hazard model identified the most significant RTKs that represented independent prognostic relevance.Significant prognostic relevance was similarly confirmed for IGF-1R (P = 0.014), and EGFR (P = 0.030), but not for EphA2 or HER2 expression.Of the 53 patients who recurred, 40 patients (75.5%) were HER3-positive.
Affiliation: Department of Surgery, Kitasato University School of Medicine, Kitasato 1-15-1, Minami-ku, Sagamihara, Kanagawa, 252-0374, Japan.Show MeSH
Related in: MedlinePlus
Mentions: We similarly constructed Kaplan Meier survival curves for analysis of the survival of patients according to the levels of expression of other RTKs. When EGFR expression was classified into IHC 1+ (n = 62; 37.1%) and IHC 2+/3+ (n = 105; 62.9%), the 5y-RFS was 78.7% and 59.6% respectively. This difference was statistically significant, and EGFR overexpression (IHC 2+/3+) also showed poor prognosis (P = 0.030) (Fig. 4a). HER2 expression was classified as follows; IHC 0 (n = 96; 57.5%), IHC 1+ (n = 52; 31.1%), IHC 2+ (n = 8; 4.8%) and IHC 3+ (n = 11; 6.6%). Unexpectedly, HER2 expression of IHC 3+ was not a prognostic factor. There was no significant difference between the survival of patients with IHC 3+ and that of patients with other HER2 IHC expression (Fig. 4b). When IGF-1R expression was classified into IHC 0 (n = 79; 47.3%) and IHC 1+/2+ (n = 88; 52.7%), the 5y-RFS was 79.9% and 56.6% respectively, and this difference was statistically significant (P = 0.014). IGF-1R overexpression (IHC 1+/2+) showed poor prognosis (Fig. 4c). EphA2 expression was also classified into IHC 0 (n = 101; 60.5%) and IHC 1+/2+ (n = 66; 39.5%), which showed a 5y-RFS of 73.7% and 57.7% respectively. This difference was not statistically significant (P = 0.054). Patients with EphA2 overexpression (IHC 1+/2+) tended to have a poor prognosis (Fig. 4d).
Affiliation: Department of Surgery, Kitasato University School of Medicine, Kitasato 1-15-1, Minami-ku, Sagamihara, Kanagawa, 252-0374, Japan.